VJHemOnc Podcast

Experts discuss the use of CAR-T therapy in lymphoma treatment in the UK, including management of toxicities, treating transplant-ineligible patients, use of steroids, eligibility criteria, challenges, and comparing CAR-T with Bespicic treatment.

Experts discuss advancements in novel targets and treatments for multiple myeloma and amyloidosis, including immunomodulatory imide drugs, monoclonal antibodies, and bispecific antibodies. They explore overcoming resistance to these drugs, immunogenic cell death, and new trial designs. The relationship between high risk myeloma and immunogenic cell death is discussed, along with approaches to treating amyloidosis. The importance of early care and treatment, personalized approaches, and targeting resistant mechanisms for achieving a cure is emphasized.

Experts discuss the impact of AI and machine learning algorithms in myelodysplastic syndromes (MDS). They explore the different types of machine learning algorithms used in AI, the challenges and potential of AI in medicine, and the considerations for using these algorithms. They also discuss the development of a machine learning prognosis tool for MDS and the importance of adopting novel technologies like AI in enhancing outcomes for patients with MDS.

Discover the transformative findings of the MMRF-CoMMpass study, mapping the genomic profile of multiple myeloma patients. Learn about specific genomic features associated with high-risk and ultra high-risk disease, and how they impact treatment responses and long-term outcomes.

Experts discuss the impact of genomics on immunotherapies and risk stratification in multiple myeloma. They explore the role of highly proliferative cells and susceptibility of dormant cells to apoptosis. Genomic data helps identify high-risk patients and understand resistance mechanisms to novel agents.

Experts discuss single-cell sequencing in understanding drug resistance and immune mechanisms in multiple myeloma. They explore the impact of chromosome 1q copy number alterations on patient outcomes and signatures of drug resistance. The interaction between tumor cells and the microenvironment in treatment response is also examined. Other topics include flow cytometry for patient prognosis and the use of proteomics, genomic, and transcriptional data to uncover rare cell events.

The podcast discusses recent advances in amyloidosis treatment, including the different types of amyloidosis and their impact on organ failure. The speakers delve into treatment approaches and clinical trial updates, highlighting the need for early detection and improvements in therapy. They also explore targeting free light chain secretion in AL amyloidosis using go-to-line amnurotoxin. Overall, the podcast provides valuable insights into the future of amyloidosis treatment and promising therapeutic strategies.

Exploring the latest updates in CAR T-cell therapies for B-cell acute lymphoblastic leukemia (B-ALL), including exciting results from Phase I trials of UCART22 and PBCAR0191. Additionally, preliminary results from a Phase I/II trial of ADCT-602, an antibody drug conjugate, are discussed. The podcast highlights the safety and efficacy of PB-CAR 0191 allogeneic CAR T cell therapy in B-cell lymphoblastic leukemia, as well as the preliminary findings of U-CARTI-22 and anti CD22 allogenic CAR T cell therapy.

The podcast discusses the limitations of current treatments for myelodysplastic syndromes (MDS) and explores emerging treatment targets and strategies, including drug combinations and cell therapies. They also explore the potential of chimeric antigen receptor (CAR) T-cell therapy and other immunotherapies for patients who fail conventional chemotherapy and stem cell transplantation. The speakers delve into the development of new agents for MDS care, targeting splicing abnormalities, and the importance of personalized care and clinical trials to improve the standard of care for MDS patients.

The podcast discusses novel developments in myeloproliferative neoplasms (MPNs), including the use of JAK 1/2 inhibitors and interferon therapy. It also explores the potential of LSD1 inhibitor IMG7289 and ropeginterferon in second-line treatment, as well as updates in the treatment of polycythemia vera and myelofibrosis. The speakers discuss the importance of predicting and preventing MPN transformation to leukemia, the evolution and standardization of practices in trials and medical practice, overall survival in new phase three trials, and exciting developments and ongoing research in MPNs.